Legal Medicine
Volume 12, Issue 2 , Pages 79-83 , March 2010

Molecular-biological analysis of the effect of methamphetamine on the heart in restrained mice

  • Kotaro Shinone

      Affiliations

    • Department of Forensic Medicine and Science, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu City, Mie 514-8507, Japan
    • ,
  • Masafumi Tomita

      Affiliations

    • Department of Medical Toxicology, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama 701-0192, Japan
    • ,
  • Hiromasa Inoue

      Affiliations

    • Department of Forensic Medicine and Science, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu City, Mie 514-8507, Japan
    • ,
  • Yasuhisa Nakagawa

      Affiliations

    • Department of Forensic Medicine and Science, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu City, Mie 514-8507, Japan
    • ,
  • Mayumi Ikemura

      Affiliations

    • Department of Forensic Medicine and Science, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu City, Mie 514-8507, Japan
    • ,
  • Masayuki Nata

      Affiliations

    • Department of Forensic Medicine and Science, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu City, Mie 514-8507, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 59 231 5014; fax: +81 59 231 5690.

Received 10 August 2009 ,Revised 13 November 2009 ,Accepted 6 January 2010.

References 

  1. Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102:1204–1211
  2. Yamamoto J. Recent trends of drug abuse in Japan. Ann NY Acad Sci. 2004;1025:430–438
  3. Inoue H, Ikeda N, Kudo K, Ishida T, Terada M, Matoba R. Methamphetamine-related sudden death with a concentration which was of a ‘toxic level’. Leg Med. 2006;8:150–155
  4. Albertson TE, Derlet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med. 1999;170:214–219
  5. Kalant H, Kalant OJ. Death in amphetamine users: causes and rates. CMA J. 1975;112:299–304
  6. Stratton SJ, Rogers C, Brickett K, Gruzinski G. Factors associated with sudden death of individuals requiring restraint for excited delirium. Am J Emerg Med. 2001;19(3):187–191
  7. Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci. 2003;73:129–140
  8. Maeno Y, Iwasa M, Inoue H, Koyama H, Matoba R. Methamphetamine induces an increase in cell size and reorganization of myofibrils in cultured adult rat cardiomyocytes. Int J Legal Med. 2000;113:201–207
  9. Maeno Y, Iwasa M, Inoue H, Koyama H, Matoba R, Nagao M. Direct effects of methamphetamine on hypertrophy and microtubules in cultured adult rat ventricular myocytes. Forensic Sci Int. 2000;113:239–243
  10. Berankova K, Habrdova V, Balikova M, Strejc P. Methamphetamine in hair and interpretation of forensic findings in a fatal case. Forensic Sci Int. 2005;153:93–97
  11. Yamamoto M, Yamazaki S, Uematsu S, Sato S, Hemmi H, Hoshino K, et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature. 2004;430:218–222
  12. Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NF-κB and C/EBPs in IκB-ζ-mediated transcriptional activation. Biochem J. 2007;405:605–615
  13. Bonta PI, Pols TW, de Vries CJ. NR4A nuclear receptors in atherosclerosis and vein-graft disease. Trends Cardiovasc Med. 2007;17:105–111
  14. Harant H, Lindley IJ. Negative cross-talk between the human orphan nuclear receptor Nur77/NAK-1/TR3 and nuclear factor-kappaB. Nucleic Acids Res. 2004;32(17):5280–5290
  15. Wang T, Zhang X, Li JJ. The role of NF-κB in the regulation of cell stress responses. Int Immunopharmacol. 2002;2:1509–1520
  16. Rahman I. Regulation of nuclear factor-κB, activator protein-1, and glutathione levels by tumor necrosis factor- and dexamethasone in alveolar epithelial cells. Biochem Pharmacol. 2000;60:1041–1049
  17. Nukina H, Sudo N, Aiba Y, Oyama N, Koga Y, Kubo C. Restraint stress elevates the plasma interleukin-6 levels in germ-free mice. J Neuroimmunol. 2001;115:46–52
  18. Scheuer DA, Mifflin SW. Repeated intermittent stress exacerbates myocardial ischemia-reperfusion injury. Am J Physiol Regulatory Integrative Comp Physiol. 1998;274:470–475
  19. Zhao Y, Wang W, Qian L. Hsp70 may protect cardiomyocytes from stress-induced injury by inhibiting Fas-mediated apoptosis. Cell Stress Chaperones. 2007;12:83–95
  20. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543–1553
  21. Matsumori A, Sasayama S. The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. Heart Fail Rev. 2001;6:129–136
  22. Knuefermann P, Vallejo J, Mann DL. The role of innate immune responses in the heart in health and disease. Trends Cardiovasc Med. 2004;14:1–7
  23. Wilson EM, Diwan A, Spinale FG, Mann DL. Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol. 2004;37(4):801–811
  24. Wang X, Liu Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cellular Signaling. 2007;19:1372–1382
  25. Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol. 2006;176:1899–1907
  26. Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol. 2006;177:7497–7504
  27. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, et al. Dynamic regulation of pro- and anti-inflammatory cytokineses by MAPK phosphatase 1 in innate immune responses. Proc Natl Acad Sci USA. 2006;103(7):2274–2279
  28. Klamp T, Boehm U, Schenk D, Pfeffer K, Howard JH. A giant GTPase, very large inducible GTPase-1, is inducible by IFNs. J Immunol. 2003;171:1255–1265
  29. Le TH, Coffman TM. Rgs2: a “turn-off” in hypertension. J Clin Invest. 2003;111:441–443
  30. Grant SL, Lassègue B, Griendling KK, Ushio-Fukai M, Lyons PR, Alexander RW. Specific regulation of RGS2 messenger RNA by angiotensin II in cultured vascular smooth muscle cells. Mol Pharmacol. 2000;57(3):460–467
  31. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest. 2003;111:445–452
  32. Tang M, Wang G, Lu P, Karas RH, Aronovitz M, Heximer SP, et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med. 2003;9(12):1506–1512
  33. Holycross BJ, Radin MJ. Cytokines I heart failure: potential interactions with angiotensin II and leptin. Mol Interv. 2002;2:424–427
  34. Sekiguchi K, Li X, Coker M, Flesch M, Barger PM, Sivasubramanian N, et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res. 2004;63:433–442
  35. Blumer JB, Smrcka AV, Lanier SM. Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling. Pharmacol Ther. 2007;113(3):488–506
  36. Massrieh W, Derjuga A, Doualla-Bell F, Ku CY, Sanborn BM, Blank V. Regulation of the MAFF transcription factor by proinflammatory cytokines in myometrial cells. Biol Reprod. 2006;74(4):699–705
  37. Blank V. Small Maf proteins in mammalian gene control: mere dimerization partners or dynamic transcriptional regulators?. J Mol Biol. 2008;376(4):913–925

PII: S1344-6223(10)00002-7

doi: 10.1016/j.legalmed.2010.01.001

Legal Medicine
Volume 12, Issue 2 , Pages 79-83 , March 2010

Article Tools

* Image Usage & Resolution